US-based healthcare technology company LANGaware has partnered with the Bioiatriki Healthcare Group, a large-scale private healthcare provider in Southeast Europe.
The collaboration aims to advance the early detection and management of neurodegenerative conditions, including Alzheimer’s disease (AD) and Mild Cognitive Impairment (MCI), in Greece and Cyprus.
Under the partnership, Bioiatriki will integrate LANGaware’s advanced AI-driven platform into its network of over 75 diagnostic centres.
The platform leverages AI to analyse digital biomarkers from voice and speech, enabling early detection of cognitive and behavioural health conditions with superior accuracy.
With the integrated technology offering, Bioiatriki allows patients to detect dementia symptoms at earlier stages, significantly enhancing patient outcomes and quality of life.
LANGaware founder and CEO Vassiliki Rentoumi said: “We are excited to collaborate with Bioiatriki Healthcare Group to bring our innovative technology to more patients.
“This partnership aligns with our mission to revolutionise early diagnosis and provide effective, accessible solutions for cognitive health management globally.”
LANGaware said its AI platform provides rapid and accurate results within minutes, based on a brief voice recording of the participant describing an image or a daily activity.
The system offers 90% sensitivity and 85% specificity in detecting AD and MCI, significantly reducing the risk of misdiagnosis and unnecessary treatments.
The integration of its technology within Bioiatriki’s healthcare services would not only improve patient outcomes but also enhance healthcare efficiency.
Its partnership with Bioiatriki will expand access to advanced diagnostic services and help improve cognitive health management, said LANGaware
